摘要
目的观察钠-葡萄糖协同转运蛋白2(sodium-dependent glucose transporters 2,SGLT-2)抑制剂(达格列净)联合芪苈强心胶囊对老年慢性心力衰竭患者心功能指标的影响。方法选取2022年8月—2023年9月于酒钢医院进行诊治的老年慢性心力衰竭患者86例为研究对象,随机分为对照组与研究组,各43例。对照组采用芪苈强心胶囊治疗,研究组接受SGLT2抑制剂联合芪苈强心胶囊治疗。经相同治疗周期后,对比两组临床疗效、心功能指标、实验室指标以及心血管不良事件发生率。结果研究组总有效率(97.67%)显著高于对照组(81.40%),差异有统计学意义(χ^(2)=7.221,P<0.05)。治疗前,两组患者左心室射血分数和左心室舒张末期内径、左心室收缩末期内径比较,差异无统计学意义(P>0.05);治疗后,两组左心室射血分数明显比治疗前高,左心室舒张末期内径、左心室收缩末期内径明显比治疗前低,且研究组患者的左心室射血分数呈更高水平,左心室舒张末期内径、左心室收缩末期内径呈更低水平,差异有统计学意义(P<0.05)。治疗前,两组超敏C反应蛋白及氨基末端脑利钠肽前体水平比较,差异无统计学意义(P>0.05)。治疗后,两组超敏C反应蛋白及氨基末端脑利钠肽前体水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。研究组心血管不良事件发生率低于对照组,差异有统计学意义(P<0.05)。结论相比于单一治疗,SGLT2抑制剂联合芪苈强心胶囊对老年慢性心力衰竭患者的临床效果更为显著,心功能可获得明显改善,临床具有较高的安全性。
Objective To observe the effects of SGLT2 inhibitor(dapagliflozin)combined with Qiliqiangxin capsule on cardiac function indexes in elderly patients with chronic heart failure.Methods A total of 86 elderly patients with chronic heart failure diagnosed and treated in Jiugang Hospital from August 2022 to september 2023 were selected as the study objects,and randomly divided into control group and study group,with 43 cases in each group.The control group was treated with Qiliqiangxin capsule,and the study group was treated with SGLT2 inhibitor combined with Qiliqiangxin capsule.After the same treatment cycle,the clinical efficacy,cardiac function indexes,laboratory indexes and the incidence of cardiovascular adverse events were compared between the two groups.Results The total effective rate of the study group(97.67%)was significantly higher than that of the control group(81.40%),and the difference was statistically significant(χ^(2)=7.221,P<0.05).Before treatment,there was no statistically significant difference in left ventricular ejection fraction,left ventricular end-diastolic diameter and left ventricular end-systolic diameter be‐tween the two groups(P>0.05).After treatment,the left ventricular ejection fraction in the two groups was significantly higher than before treatment,and the left ventricular end-diastolic diameter and the left ventricular end-systolic diam‐eter were significantly lower than before treatment,and the left ventricular ejection fraction in the study group was higher,and the left ventricular end-diastolic diameter and the left ventricular end-systolic diameter were lower,the difference was statistical significance(P<0.05).Before treatment,there was no statistically significant difference in the levels of hypersensitive C-reactive protein and amino terminal brain natriuretic peptide between the two groups(P>0.05).After treatment,the levels of hypersensitive C-reactive protein and amino terminal brain natriuretic peptide in the two groups were lower than before treatment,and the study group was lower than the control group,the difference was statistically significant(P<0.05).The incidence of cardiovascular adverse events in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Compared with single treatment,SGLT2 inhibitor combined with Qiliqiangxin capsule has a more significant clinical effect on elderly patients with chronic heart failure,with significant improvement in cardiac function and high clinical safety.
作者
王红伍
肖淑云
袁忠孝
李保明
宋新海
WANG Hongwu;XIAO Shuyun;YUAN Zhongxiao;LI Baoming;SONG Xinhai(Department of Geriatrics,Jiugang Hospital,Jiayuguan,Gansu Province,735100 China)
出处
《系统医学》
2023年第21期9-13,共5页
Systems Medicine
基金
嘉峪关市科技计划项目(23-B01)。
